1
|
Lu Z, Zhang Y, Yan X, Chen Y, Tao X, Wang J, Jia N, Lyu T, Wang J, Ding J, Feng W, Hua K. Estrogen stimulates the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway and regulation of its downstream targets E‑cadherin and α‑actinin‑4. Mol Med Rep 2014; 10:2433-40. [PMID: 25216292 DOI: 10.3892/mmr.2014.2561] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Accepted: 05/09/2014] [Indexed: 11/06/2022] Open
Abstract
Previous studies by our group revealed that the phosphoinositide 3‑kinase (PI3K)/AKT pathway was involved in estrogen‑induced metastasis in ovarian cancer cells. In the present study, the role and mechanism of estrogen‑induced invasion was further explored using a stable short hairpin RNA (shRNA) estrogen receptor α/β (ER α/β) SKOV3 cell line when ER α and ER β were knocked down by lentiviral infection. The effects of estrogen and LY294002, a PI3K inhibitor, on the invasion of shRNA ER α/β SKOV3 cells were evaluated in vitro and in vivo. 17‑β estradiol promoted cell invasion, activated phosphorylated AKT in a dose‑ and time‑dependent manner, decreased E‑cadherin and increased cytoplasmic α‑actinin‑4 expression. When the PI3K/AKT pathway was suppressed by LY294002, the effect of estrogen was attenuated. Estrogen stimulated the growth of shRNA ER α/β SKOV3 xenograft tumors in nude mice, whereas LY294002 inhibited the growth and antagonized the effect of estrogen. The results indicate that estrogen promotes the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway, downregulation of E‑cadherin and upregulation of α‑actinin‑4 in an ER‑independent manner. Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma.
Collapse
Affiliation(s)
- Zhiying Lu
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Ying Zhang
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Xiaohui Yan
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Yisong Chen
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Xiang Tao
- Department of Pathology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Jiajia Wang
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Nan Jia
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Tianjiao Lyu
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Junyan Wang
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Jingxin Ding
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Weiwei Feng
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| | - Keqin Hua
- Department of Gynecology, The Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
| |
Collapse
|